|
Encorafenib Clinical Trials
13 actively recruiting trials across 5 locations
Also known as: Braftovi, LGX 818, LGX-818, LGX818
Other6 trials
Iowa City, Iowa2 trials
Houston, Texas2 trials
Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases
M D Anderson Cancer Center
Phase 2
Birmingham, Alabama1 trial
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
University of Alabama at Birmingham Cancer Center
Phase 2
Irvine, California1 trial
Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
Phase 1
Bethesda, Maryland1 trial
Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL
National Institutes of Health Clinical Center
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.